-
11.发明公开
公开(公告)号：EP2971149A1
公开(公告)日：2016-01-20
申请号：EP14768369.2
申请日：2014-03-13
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , A61B1/31 , A61B10/0038 , A61B10/0051 , A61B10/007 , A61B10/04 , C12Q2600/154
摘要： Embodiments provide methods and compositions related to detecting neoplasia in ulcerative colitis patients by detection and analysis of the methylation state of miR-1, -9, -124, miR-137 and/or miR-34b/c in samples from UC patients.
摘要翻译： 实施方案通过检测和分析来自UC患者的样品中miR-1，-9，-124，miR-137和/或miR-34b / c的甲基化状态，提供与检测溃疡性结肠炎患者的瘤形成有关的方法和组合物。
-
公开(公告)号：EP2825671A1
公开(公告)日：2015-01-21
申请号：EP13761285.9
申请日：2013-03-13
发明人： O'GARRA, Anne , BLOOM, Chloe , BERRY, Matthew, Paul Reddoch , WILKINSON, Robert , BANCHEREAU, Jacques, F. , CHAUSSABEL, Damien , PASCUAL, Maria, Virginia
CPC分类号： C12Q1/6883 , A61K31/133 , A61K31/455 , A61K31/496 , A61K31/4965 , C12Q1/68 , C12Q2600/118 , C12Q2600/158 , G01N33/48 , G01N33/68 , G01N33/6893 , G01N2333/35 , G01N2800/26 , G01N2800/52
摘要： The present invention includes methods for early detection of a treatment response in a patient suspected of being infected with
Mycobacterium tuberculosis . Changes in the blood transcriptome are detectable within two weeks of the initiation of antituberculosis therapy.-
公开(公告)号：EP2798081A1
公开(公告)日：2014-11-05
申请号：EP12808661.8
申请日：2012-12-21
IPC分类号： C12Q1/68 , G01N33/564
CPC分类号： C12Q1/6888 , A61K31/56 , A61K31/616 , A61K2039/505 , C07K16/00 , C12Q1/6883 , C12Q2600/158 , G01N33/564 , G01N33/74 , G01N2333/49 , G01N2800/52 , G06F19/20
摘要： Biomarkers of Kawasaki Disease (KD) are provided. In certain aspects, methods are provided for detecting KD biomarkers, such as elevated PDGFC expression. Likewise, methods of treating a subject having a biomarker of KD are described.
-
公开(公告)号：EP2688592A1
公开(公告)日：2014-01-29
申请号：EP12765865.6
申请日：2012-03-26
IPC分类号： A61K39/395 , A61P31/12 , C07K16/46 , A61K39/29 , A61P37/04 , C12N5/0784
CPC分类号： C12N5/0639 , A61K39/12 , A61K39/29 , A61K2039/6056 , C07K14/005 , C07K16/2851 , C07K16/2878 , C07K2319/00 , C07K2319/33 , C12N2770/24222 , C12N2770/24234
摘要： Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.
-
15.发明公开Multivariable antigens complexed with targeting humanized monoclonal antibody 审中-公开Mit einem zielgerichteten menschlichen monokacrylenAntikörperkomplexierte multivariable Antigene
公开(公告)号：EP2684889A2
公开(公告)日：2014-01-15
申请号：EP13178012.4
申请日：2008-01-31
发明人： Zurawski, Gerard
IPC分类号： C07K2/00 , C07K16/46 , A61K39/00 , A61K38/19 , C12P21/06 , C12P19/00 , C12N1/20 , C07H21/04 , C07K19/00 , C07K14/33 , C07K16/00
CPC分类号： C07K16/28 , A61K39/44 , C07K14/33 , C07K16/00 , C07K2317/24 , C07K2317/35 , C07K2317/54 , C07K2317/55 , C07K2319/00 , C07K2319/33 , Y02A50/472
摘要： The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates.
摘要翻译： 本发明包括用于设计，制备和使用模块化重组抗体或其片段的组合物和方法，所述重组抗体或其片段具有允许多变抗原缀合物的快速装配的一半粘附素 - 停泊聚糖对。
-
16.发明公开Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis 审中-公开通过血液白细胞微阵列分析诊断转移性黑素瘤和监测免疫抑制指标
公开(公告)号：EP2570951A1
公开(公告)日：2013-03-20
申请号：EP12196232.8
申请日：2007-11-03
IPC分类号： G06F19/00
CPC分类号： G06F19/20 , C12Q1/6837 , C12Q1/6886 , C12Q2600/158 , G06F19/18
摘要： The present invention includes compositions, systems and methods for the early detection and consistent determination of metastatic melanoma and/or immunosuppression using microarrays by calculating one or more expression vectors from the expression of one or more genes.
摘要翻译： 本发明包括通过从一种或多种基因的表达计算一种或多种表达载体，使用微阵列来早期检测和一致确定转移性黑素瘤和/或免疫抑制的组合物，系统和方法。
-
17.发明公开DENDRITIC CELL IMMUNORECEPTORS (DCIR)-MEDIATED CROSSPRIMING OF HUMAN CD8+ T CELLS 审中-公开树突状细胞免疫受体交换交叉吸人CD8 + T细胞
公开(公告)号：EP2566518A1
公开(公告)日：2013-03-13
申请号：EP11778288.8
申请日：2011-05-04
CPC分类号： A61K39/385 , A61K38/162 , A61K2039/6056 , C07K16/2851 , C07K2317/76 , C07K2319/00 , Y02A50/39 , Y02A50/403 , Y02A50/41 , Y02A50/412 , Y02A50/414
摘要： Immunostimulatory compositions and methods comprising an ITIM motif-containing DC immunoreceptor (DCIR) to mediate potent crosspresentation are described herein. The inventors evaluated human CD8+ T cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific CD8+ T cell immunity by all human DC subsets including ex vivo generated DCs, skin-isolated Langerhans cells and blood mDCs and pDCs. Enhanced specific CD8+ T cell responses were observed when antigens like, FluMP, MART-1, viral (HIV gag), etc. were delivered to the DCs via DCIR, compared to those induced by a free antigen, or antigen conjugated to a control mAb or delivered via DC-SIGN, another lectin receptor. Addition of Toll-like receptor (TLR) 7/8-agonist enhanced DCIR-mediated crosspresentation as well as crosspriming. Thus, antigen targeting via the human DCIR receptor allows activation of specific CD8+ T cell immunity.
-
18.发明授权THERAPEUTIC APPLICATIONS OF ACTIVATION OF HUMAN ANTIGEN-PRESENTING CELLS THROUGH DECTIN-1 有权细胞与人抗原的BY的Dectin-1的活化治疗应用
公开(公告)号：EP2129773B1
公开(公告)日：2013-02-13
申请号：EP08799678.1
申请日：2008-02-22
IPC分类号： C12N5/07 , A61K39/395 , C07K16/28
CPC分类号： C07K16/2851 , A61K39/395 , A61K2039/5154 , A61K2039/5158 , C07K16/1018 , C07K2317/24 , C07K2317/74 , C07K2317/92 , C07K2319/00 , C12N5/0639 , C12N9/2402 , C12N2501/22 , C12N2501/23 , C12N2501/50 , C12N2501/998
-
19.发明公开INVOLVEMENT OF ANDROGEN/ANDROGEN RECEPTOR PATHWAY IN FABRY DISEASE 审中-公开雄激素/ ANDROGENREZEPTORPFAD到模式FABRY参与
公开(公告)号：EP2542687A1
公开(公告)日：2013-01-09
申请号：EP11751240.0
申请日：2011-03-01
发明人： SHEN, Jinsong , SCHIFFMANN, Raphael , MENG, Xingli
IPC分类号： C12Q1/00 , A61P3/00 , G01N33/483 , A61K38/00 , A61P5/26 , G01N33/487
CPC分类号： G01N33/743
摘要： Novel therapies for the treatment of Fabry disease by using androgen/androgen receptor (AR) pathway-related molecules as biomarkers and use of approaches targeting androgen/AR pathway are presented herein. The involvement of aberrant androgen/AR pathway in Fabry disease has never been previously described. The present invention describes, (i) use of approaches that target androgen/AR pathway as therapeutic treatments for Fabry disease and (2) use of the levels of androgen/AR pathway-related molecules in body fluids or tissues as biomarkers for evaluation of disease progression and efficacy of treatments in Fabry patients.
-
20.发明公开Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells 审中-公开目标抗原基因定位抗原抗原一抗DCIR，抗原特异性抗体
公开(公告)号：EP2527363A1
公开(公告)日：2012-11-28
申请号：EP12164572.5
申请日：2008-02-01
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/2851 , A61K39/02 , A61K39/12 , A61K39/145 , A61K39/21 , A61K47/6897 , A61K47/6901 , A61K2039/505 , A61K2039/6056 , B82Y5/00 , C12N5/0639 , C12N2760/16134
摘要： The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
摘要翻译： 本发明包括使用形成抗体 - 抗原复合物的抗原附着的DCIR特异性抗体或其片段增加抗原呈递的有效性的组合物和方法，其中所述抗原由具有抗体 - 抗原复合物的树突状细胞加工和呈递， 与抗体 - 抗原复合物接触。
-
-
-
-
-
-
-
-
-
搜索结果
162 条记录 (耗时 0.04 秒)
